BioWorld: The Daily Biopharmaceutical and Medical Technology …
These cookies are used to enable social media sharing or “like” buttons on our services. They also provide the ability to link your account or engage with our content on or through a social media platform such as Facebook, Twitter or LinkedIn.
BioWorld: The Daily Biopharmaceutical News Source
6 days ago · With Alhemo (concizumab-mtci) from Novo Nordisk A/S, a third hemophilia drug in the past eight months has been approved by the U.S. FDA. The once-daily injectable prophylaxis is to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or B with inhibitors.
LY-4175408, a novel PTK7-targeting ADC with improved potency …
Nov 6, 2024 · Researchers from Eli Lilly & Co. presented the discovery and preclinical characterization of a novel protein tyrosine kinase 7 (PTK7)-targeting antibody-drug conjugate (ADC), LY-4175408, being developed for the treatment of cancer.
Pfizer patents new compounds targeting GTPase KRAS
Oct 30, 2024 · Pfizer Inc. has disclosed drugs targeting GTPase KRAS and its mutant forms reported to be useful for the treatment of cancer.
China - Articles - BioWorld
5 days ago · China's National Medical Products Administration (NMPA) approved Innovent Biologics Inc.’s NDA for Dovbleron (taletrectinib), a next-generation ROS1 tyrosine kinase inhibitor (TKI), for treating adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who have been previously treated with ROS1 TKIs.
M-3913, a first-in-class ERSM with efficacy in models of MM
Apr 18, 2023 · At the AACR meeting this week, EMD Serono Inc. reported the discovery of a novel endoplasmic reticulum (ER) stress modulator (ERSM), M-3913.
Gilead latest as all PD-1 agonist boats lifted by rising tide
Gilead Sciences Inc. is aiming to capitalize on the early August 2022 buyout of privately held U.K. biotech Mirobio Ltd. with the advancement of PD-1 agonist GS-0151 into phase Ib trials for rheumatoid arthritis, a decision that Leerink analyst David Risinger hailed as positive for others at work with the intriguing mechanism. Paying $405 million for …
Preclinical characterization of AZD-9592, an EGFR–c-Met
Apr 19, 2023 · Researchers from Astrazeneca plc presented preclinical data for AZD-9592, the novel epidermal growth factor (EGFR)–c-Met bispecific antibody-drug conjugate (ADC) targeting key oncogenic drivers in non-small-cell lung cancer (NSCLC).
Allianthera (Suzhou) Biopharmaceutical patents new aryl
Jun 9, 2023 · Allianthera (Suzhou) Biopharmaceutical Co. Ltd. has patented new aryl hydrocarbon receptor (AhR) agonists reported to be useful for the treatment of cancer, lung diseases, bone, dermatological, eye, gastrointestinal, neurological and pancreatic disorders, among others.
| BioWorld
Nov 21, 2000 · Breaking news and analysis of the global biotechnology, pharmaceutical, medical device and medical technology sectors. In-depth coverage of innovation, business, financing, regulation, science, product development, clinical trials and more